ADICON Holdings IPO: The Bull Case
The key elements of the bull case rest on the growing non-COVID-19 testing addressable market, improving market sentiment, strong non-COVID-19...
440 Views
Kindstar (åŗ·å£ēÆē) IPO Trading: Pattern of Demand Divergence
We look at the updates on Kindstar IPO since our last note. With its valuation higher than leading ICL peer, we do not expect a strong debut...
478 Views
ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
795 Views
Kindstar Globalgene IPO: Valuation Insights
At the mid-point of the IPO price range, the total net proceeds are HK$1,931.1 million ($250 million). Overall, we would participate in the IPO due...
597 Views
Kindstar Globalgene (åŗ·å£ēÆē) IPO: Fairly Valued for a Questionable Moat
We think Kindstar is fairly valued for its fundamentals. Its moat is not as wide as many investors would think. Therefore we would avoid the deal.
543 Views